Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carol A. Glaser is active.

Publication


Featured researches published by Carol A. Glaser.


JAMA | 2009

Factors Associated With Death or Hospitalization Due to Pandemic 2009 Influenza A(H1N1) Infection in California

Janice K. Louie; Meileen Acosta; Kathleen Winter; Cynthia Jean; Shilpa Gavali; Robert Schechter; Duc J. Vugia; Kathleen Harriman; Bela T. Matyas; Carol A. Glaser; Michael C. Samuel; Jon Rosenberg; John Talarico; Douglas Hatch

CONTEXT Pandemic influenza A(H1N1) emerged rapidly in California in April 2009. Preliminary comparisons with seasonal influenza suggest that pandemic 2009 influenza A(H1N1) disproportionately affects younger ages and causes generally mild disease. OBJECTIVE To describe the clinical and epidemiologic features of pandemic 2009 influenza A(H1N1) cases that led to hospitalization or death. DESIGN, SETTING, AND PARTICIPANTS Statewide enhanced public health surveillance of California residents who were hospitalized or died with laboratory evidence of pandemic 2009 influenza A(H1N1) infection reported to the California Department of Public Health between April 23 and August 11, 2009. MAIN OUTCOME MEASURE Characteristics of hospitalized and fatal cases. RESULTS During the study period there were 1088 cases of hospitalization or death due to pandemic 2009 influenza A(H1N1) infection reported in California. The median age was 27 years (range, <1-92 years) and 68% (741/1088) had risk factors for seasonal influenza complications. Sixty-six percent (547/833) of those with chest radiographs performed had infiltrates and 31% (340/1088) required intensive care. Rapid antigen tests were falsely negative in 34% (208/618) of cases evaluated. Secondary bacterial infection was identified in 4% (46/1088). Twenty-one percent (183/884) received no antiviral treatment. Overall fatality was 11% (118/1088) and was highest (18%-20%) in persons aged 50 years or older. The most common causes of death were viral pneumonia and acute respiratory distress syndrome. CONCLUSIONS In the first 16 weeks of the current pandemic, the median age of hospitalized infected cases was younger than is common with seasonal influenza. Infants had the highest hospitalization rates and persons aged 50 years or older had the highest mortality rates once hospitalized. Most cases had established risk factors for complications of seasonal influenza.


Annals of Neurology | 2009

Anti–N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis in Children and Adolescents

Nicole R. Florance; Rebecca Davis; Christopher Lam; Christina L. Szperka; Lei Zhou; Saba Ahmad; Cynthia J. Campen; Heather E. Moss; Nadja Peter; Amy J. Gleichman; Carol A. Glaser; David R. Lynch; Myrna R. Rosenfeld; Josep Dalmau

To report the clinical features of anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in patients ≤ 18 years old.


Clinical Infectious Diseases | 2008

The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America

Allan R. Tunkel; Carol A. Glaser; Karen C. Bloch; James J. Sejvar; Christina M. Marra; Karen L. Roos; Barry J. Hartman; Sheldon L. Kaplan; W. Michael Scheld; Richard J. Whitley

Guidelines for the diagnosis and treatment of patients with encephalitis were prepared by an Expert Panel of the Infectious Diseases Society of America. The guidelines are intended for use by health care providers who care for patients with encephalitis. The guideline includes data on the epidemiology, clinical features, diagnosis, and treatment of many viral, bacterial, fungal, protozoal, and helminthic etiologies of encephalitis and provides information on when specific etiologic agents should be considered in individual patients with encephalitis.


Clinical Infectious Diseases | 2006

Beyond Viruses: Clinical Profiles and Etiologies Associated with Encephalitis

Carol A. Glaser; Somayeh Honarmand; Lydia Anderson; David P. Schnurr; Bagher Forghani; Cynthia K. Cossen; Frederick L. Schuster; L. J. Christie; J. H. Tureen

BACKGROUND Encephalitis is a complex syndrome, and its etiology is often not identified. The California Encephalitis Project was initiated in 1998 to identify the causes and further describe the clinical and epidemiologic characteristics of encephalitis. METHODS A standardized report form was used to collect demographic and clinical data. Serum, cerebrospinal fluid, and respiratory specimens were obtained prospectively and were tested for the presence of herpesviruses, arboviruses, enteroviruses, measles, respiratory viruses, Chlamydia species, and Mycoplasma pneumoniae. The association between an identified infection and encephalitis was defined using predetermined, organism-specific criteria for confirmed, probable, or possible causes. RESULTS From 1998 through 2005, a total of 1570 patients were enrolled. Given the large number of patients, subgroups of patients with similar clinical characteristics and laboratory findings were identified. Ten clinical profiles were described. A confirmed or probable etiologic agent was identified for 16% of cases of encephalitis: 69% of these agents were viral; 20%, bacterial; 7%, prion; 3%, parasitic; and 1%, fungal. An additional 13% of cases had a possible etiology identified. Many of the agents classified as possible causes are suspected but have not yet been definitively demonstrated to cause encephalitis; these agents include M. pneumoniae (n=96), influenza virus (n=22), adenovirus (n=14), Chlamydia species (n=10), and human metapneumovirus (n=4). A noninfectious etiology was identified for 8% of cases, and no etiology was found for 63% of cases. CONCLUSIONS Although the etiology of encephalitis remains unknown in most cases, the recognition of discrete clinical profiles among patients with encephalitis should help focus our efforts toward understanding the etiology, pathogenesis, course, and management of this complex syndrome.


Clinical Infectious Diseases | 2012

The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project

Mary S. Gable; Heather Sheriff; Josep Dalmau; Drake H. Tilley; Carol A. Glaser

BACKGROUND In 2007, the California Encephalitis Project (CEP), which was established to study the epidemiology of encephalitis, began identifying cases of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Increasing numbers of anti-NMDAR encephalitis cases have been identified at the CEP, and this form rivals commonly known viral etiologies as a causal agent. We report here the relative frequency and differences among encephalitides caused by anti-NMDAR and viral etiologies within the CEP experience. METHODS Demographic, frequency, and clinical data from patients with anti-NMDAR encephalitis are compared with those with viral encephalitic agents: enterovirus, herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and West Nile virus (WNV). All examined cases presented to the CEP between September 2007 and February 2011 and are limited to individuals aged ≤30 years because of the predominance of anti-NMDAR encephalitis in this group. The diagnostic costs incurred in a single case are also included. RESULTS Anti-NMDAR encephalitis was identified >4 times as frequently as HSV-1, WNV, or VZV and was the leading entity identified in our cohort. We found that 65% of anti-NMDAR encephalitis occurred in patients aged ≤18 years. This disorder demonstrated a predilection, which was not observed with viral etiologies, for females (P < .01). Seizures, language dysfunction, psychosis, and electroencephalographic abnormalities were significantly more frequent in patients with anti-NMDAR encephalitis (P < .05), and autonomic instability occurred exclusively in this group. DISCUSSION Anti-NMDAR encephalitis rivals viral etiologies as a cause of encephalitis within the CEP cohort. This entity deserves a prominent place on the encephalitic differential diagnosis to avoid unnecessary diagnostic and treatment costs, and to permit a more timely treatment.


Clinical Infectious Diseases | 2003

In Search of Encephalitis Etiologies: Diagnostic Challenges in the California Encephalitis Project, 1998—2000

Carol A. Glaser; Sabrina Gilliam; David P. Schnurr; Bagher Forghani; Somayeh Honarmand; Nino Khetsuriani; Marc Fischer; Cynthia K. Cossen; Larry J. Anderson

The California Encephalitis Project was initiated in June 1998 to identify the causes and characterize the clinical and epidemiologic features of encephalitis in California. Testing for >or=13 agents, including herpesviruses, enteroviruses, arboviruses, Bartonella species, Chlamydia species, and Mycoplasma pneumoniae, was performed at the Viral and Rickettsial Disease Laboratory (Richmond, California). Epidemiologic and clinical information collected for each case guided further testing. From June 1998 through December 2000, 334 patients who met our case definition of encephalitis were enrolled. A confirmed or probable viral agent of encephalitis was found in 31 cases (9%), a bacterial agent was found in 9 cases (3%), and a parasitic agent was found in 2 cases (1%). A possible etiology was identified in 41 cases (12%). A noninfectious etiology was identified in 32 cases (10%), and a nonencephalitis infection was identified in 11 (3%). Despite extensive testing and evaluation, the etiology of 208 cases (62%) remained unexplained.


Emerging Infectious Diseases | 2003

Human Neurobrucellosis with Intracerebral Granuloma Caused by a Marine Mammal Brucella spp.

Annette H. Sohn; Will S. Probert; Carol A. Glaser; Nalin Gupta; Andrew W. Bollen; Jane D. Wong; Elizabeth M. Grace; William C. McDonald

We present the first report of community-acquired human infections with marine mammal–associated Brucella spp. and describe the identification of these strains in two patients with neurobrucellosis and intracerebral granulomas. The identification of these isolates as marine mammal strains was based on omp2a sequence and amplification of the region flanking bp26.


Clinical Infectious Diseases | 2013

Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium

Arun Venkatesan; Allan R. Tunkel; Karen C. Bloch; Adam S. Lauring; James J. Sejvar; Ari Bitnun; Jean Paul Stahl; A. Mailles; M. Drebot; Charles E. Rupprecht; Jonathan S. Yoder; Jennifer R. Cope; Michael R. Wilson; Richard J. Whitley; John S. Sullivan; Julia Granerod; Cheryl A. Jones; Keith Eastwood; Katherine N. Ward; David N. Durrheim; M. V. Solbrig; L. Guo-Dong; Carol A. Glaser; Heather Sheriff; David W. Brown; Eileen C. Farnon; Sharon Messenger; Beverley J. Paterson; Ariane Soldatos; Sharon L. Roy

BACKGROUND Encephalitis continues to result in substantial morbidity and mortality worldwide. Advances in diagnosis and management have been limited, in part, by a lack of consensus on case definitions, standardized diagnostic approaches, and priorities for research. METHODS In March 2012, the International Encephalitis Consortium, a committee begun in 2010 with members worldwide, held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study. RESULTS We present a consensus document that proposes a standardized case definition and diagnostic guidelines for evaluation of adults and children with suspected encephalitis. In addition, areas of research priority, including host genetics and selected emerging infections, are discussed. CONCLUSIONS We anticipate that this document, representing a synthesis of our discussions and supported by literature, will serve as a practical aid to clinicians evaluating patients with suspected encephalitis and will identify key areas and approaches to advance our knowledge of encephalitis.


Annals of Neurology | 2014

Herpes simplex virus encephalitis is a trigger of brain autoimmunity

Thaís Armangue; Frank Leypoldt; Ignacio Málaga; Miquel Raspall-Chaure; Itxaso Martí; Charles Nichter; John Pugh; Mònica Vicente-Rasoamalala; Miguel Lafuente‐Hidalgo; Alfons Macaya; Michael Ke; Maarten J. Titulaer; Romana Höftberger; Heather Sheriff; Carol A. Glaser; Josep Dalmau

In 5 prospectively diagnosed patients with relapsing post–herpes simplex encephalitis (HSE), N‐methyl‐D‐aspartate receptor (NMDAR) antibodies were identified. Antibody synthesis started 1 to 4 weeks after HSE, preceding the neurological relapse. Three of 5 patients improved postimmunotherapy, 1 spontaneously, and 1 has started to improve. Two additional patients with NMDAR antibodies, 9 with unknown neuronal surface antibodies, and 1 with NMDAR and unknown antibodies, were identified during retrospective assessment of 34 HSE patients; the frequency of autoantibodies increased over time (serum, p = 0.004; cerebrospinal fluid, p = 0.04). The 3 retrospectively identified NMDAR antibody–positive patients also had evidence of relapsing post‐HSE. Overall, these findings indicate that HSE triggers NMDAR antibodies and potentially other brain autoimmunity. Ann Neurol 2014;75:317–323


Lancet Infectious Diseases | 2015

A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study

Alexander L. Greninger; Samia N. Naccache; Kevin Messacar; Anna Clayton; Guixia Yu; Sneha Somasekar; Scot Federman; Doug Stryke; Christopher Anderson; Shigeo Yagi; Sharon Messenger; Debra A. Wadford; Dongxiang Xia; James Watt; Keith Van Haren; Samuel R. Dominguez; Carol A. Glaser; Grace M. Aldrovandi; Charles Y. Chiu

BACKGROUND Enterovirus D68 was implicated in a widespread outbreak of severe respiratory illness across the USA in 2014 and has also been reported sporadically in patients with acute flaccid myelitis. We aimed to investigate the association between enterovirus D68 infection and acute flaccid myelitis during the 2014 enterovirus D68 respiratory outbreak in the USA. METHODS Patients with acute flaccid myelitis who presented to two hospitals in Colorado and California, USA, between Nov 24, 2013, and Oct 11, 2014, were included in the study. Additional cases identified from Jan 1, 2012, to Oct 4, 2014, via statewide surveillance were provided by the California Department of Public Health. We investigated the cause of these cases by metagenomic next-generation sequencing, viral genome recovery, and enterovirus D68 phylogenetic analysis. We compared patients with acute flaccid myelitis who were positive for enterovirus D68 with those with acute flaccid myelitis but negative for enterovirus D68 using the two-tailed Fishers exact test, two-sample unpaired t test, and Mann-Whitney U test. FINDINGS 48 patients were included: 25 with acute flaccid myelitis, two with enterovirus-associated encephalitis, five with enterovirus-D68-associated upper respiratory illness, and 16 with aseptic meningitis or encephalitis who tested positive for enterovirus. Enterovirus D68 was detected in respiratory secretions from seven (64%) of 11 patients comprising two temporally and geographically linked acute flaccid myelitis clusters at the height of the 2014 outbreak, and from 12 (48%) of 25 patients with acute flaccid myelitis overall. Phylogenetic analysis revealed that all enterovirus D68 sequences associated with acute flaccid myelitis grouped into a clade B1 strain that emerged in 2010. Of six coding polymorphisms in the clade B1 enterovirus D68 polyprotein, five were present in neuropathogenic poliovirus or enterovirus D70, or both. One child with acute flaccid myelitis and a sibling with only upper respiratory illness were both infected by identical enterovirus D68 strains. Enterovirus D68 viraemia was identified in a child experiencing acute neurological progression of his paralytic illness. Deep metagenomic sequencing of cerebrospinal fluid from 14 patients with acute flaccid myelitis did not reveal evidence of an alternative infectious cause to enterovirus D68. INTERPRETATION These findings strengthen the putative association between enterovirus D68 and acute flaccid myelitis and the contention that acute flaccid myelitis is a rare yet severe clinical manifestation of enterovirus D68 infection in susceptible hosts. FUNDING National Institutes of Health, University of California, Abbott Laboratories, and the Centers for Disease Control and Prevention.

Collaboration


Dive into the Carol A. Glaser's collaboration.

Top Co-Authors

Avatar

Shigeo Yagi

California Department of Public Health

View shared research outputs
Top Co-Authors

Avatar

Heather Sheriff

California Health and Human Services Agency

View shared research outputs
Top Co-Authors

Avatar

Janice K. Louie

California Department of Public Health

View shared research outputs
Top Co-Authors

Avatar

David P. Schnurr

California Department of Public Health

View shared research outputs
Top Co-Authors

Avatar

Kathleen Harriman

California Department of Public Health

View shared research outputs
Top Co-Authors

Avatar

Karen C. Bloch

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sharon Messenger

California Department of Public Health

View shared research outputs
Top Co-Authors

Avatar

Somayeh Honarmand

California Department of Public Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge